Trial Profile
Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Aug 2019
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary)
- Indications Cancer metastases; Osteosarcoma
- Focus Therapeutic Use
- Sponsors Eleison Pharmaceuticals
- 12 Mar 2018 Status changed from active, no longer recruiting to completed, according to the Windtree Therapeutics
- 05 Feb 2018 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
- 05 Feb 2018 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2018.